- Nuclear Accident in Illinois; Guards say Shelter in Place; Honeywell it all Stayed on Site
- Reports Differ on Injuries at Metropolis Nuclear Plant Following Leakage of Uranium Hexafluoride
- OP-ED: Break-ups, Rejections and School Shootings: Educate Youth for Resiliency
- City Hall Trick or Treat
- CARIBBEAN VIEW: Not only cricket but West Indian self-worth at stake
- Over the Highway and to the Trench Contaminated Huntington Materials Exposed Many
- Honeywell, NRC Dispute Report of College Students Operating Nuclear Plant; HNN Source Alleges Book Trained Replacement Workers Operated Plant
- Huntington Judge Added to Dancing with Pros
- MILITARY-INDUSTRIAL COMPLEX: Defense Dept. Contracts for Oct. 29, 2014
- New Gaming Arcade Business Opening in Downtown Huntington
MIIR lecture series to feature drug discovery pioneer
The talk titled "Translating Your Research Discoveries into Practice: It Takes a Village!" will begin at 11 a.m. Wednesday, June 25, in Room 109 of the Robert C. Byrd Biotechnology Science Center on Marshall University's Huntington campus. The event is part of a series of public lectures hosted by the Marshall Institute for Interdisciplinary Research.
Wang is the Warner-Lambert/Parke-Davis Professor of Medicine and professor of internal medicine and pharmacology in the University of Michigan Medical School, and professor of medicinal chemistry in the College of Pharmacy. He also serves as co-director of the Molecular Therapeutics Program at the University of Michigan Comprehensive Cancer Center and is the director of the Cancer Drug Discovery Program. He is editor-in-chief of the Journal of Medicinal Chemistry, the most-cited journal in the field.
As part of his research, Wang's laboratory has successfully developed several classes of anticancer drugs designed to specifically kill tumor cells while leaving normal cells unharmed.
His work has resulted in 33 U.S. patents and four license agreements.
He co-founded Ascenta Therapeutics with former Michigan faculty members Drs. Marc Lippman and Dajun Yang in 2003, and established Ascentage Pharma Group in 2009. More recently, he created OncoFusion Therapeutics with fellow faculty member Dr. Arul Chinnaiyan to develop personalized cancer therapies.
To date, he has advanced four novel cancer drugs into Phase I/II clinical development and several more drugs into late-stage preclinical development.
Wang received a B.S. in chemistry from Peking University in 1986 and a Ph.D. in chemistry from Case Western Reserve University in 1992. After completing postdoctoral training in drug design at the National Cancer Institute in 1996, he served as assistant and associate professor at Georgetown University until 2001. He then joined the faculty at the University of Michigan Medical School as a tenured associate professor in 2001 and was promoted to professor in 2006.
In March, he was honored with the University of Michigan's Distinguished University Innovator Award, which honors faculty who have made important and lasting contributions to society by developing novel ideas and insights through their research, and then translating them to practice.
For more information about the program, contact Hollie Bailey at firstname.lastname@example.org or 304-696-3549.